Applying novel nanotechnology based approaches to develop vaccines for infectious disease and cancer. Vedantra's lead programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings.
The immune system has evolved to recognize pathogens as foreign and dangerous due to the presence of a variety of pathogen-associated molecular patterns (PAMPS), which have been shown to be good adjuvants. A successful vaccine must present simultaneously a PAMP danger signal and an antigen from a pathogen to the cells of the immune system. This is best accomplished by packaging antigen and danger signal into or onto a particle about the size of a virus.
Vedantra's (ICMV's), provide a novel, convenient and efficient way to deliver the antigen and adjuvent signals to the right cells in a context that mimics an infection.
Vedantra’s ICMVs can accommodate a range of antigens and adjuvants due to the self-assembling nature of lipid nanoparticles. These particles are stabilized by mild cross-linking techniques.